SARS-CoV-2 vaccine and increased myocarditis mortality risk: A population based comparative study in Japan
View ORCID ProfileSintaroo Watanabe, View ORCID ProfileRokuro Hama
doi: https://doi.org/10.1101/2022.10.13.22281036
Sintaroo Watanabe
1Japan Marine United Corporation, Kure Shipyard, Kure, Japan
MD, PhDRokuro Hama
2Non-profit Organization “Japan Institute of Pharmacovigilance (Med Check)”, Osaka, Japan
MDArticle usage
Posted December 22, 2022.
SARS-CoV-2 vaccine and increased myocarditis mortality risk: A population based comparative study in Japan
Sintaroo Watanabe, Rokuro Hama
medRxiv 2022.10.13.22281036; doi: https://doi.org/10.1101/2022.10.13.22281036
Subject Area
Subject Areas
- Addiction Medicine (400)
- Allergy and Immunology (711)
- Anesthesia (204)
- Cardiovascular Medicine (2961)
- Dermatology (250)
- Emergency Medicine (443)
- Epidemiology (12768)
- Forensic Medicine (12)
- Gastroenterology (829)
- Genetic and Genomic Medicine (4604)
- Geriatric Medicine (420)
- Health Economics (731)
- Health Informatics (2935)
- Health Policy (1069)
- Hematology (390)
- HIV/AIDS (927)
- Medical Education (429)
- Medical Ethics (116)
- Nephrology (472)
- Neurology (4384)
- Nursing (237)
- Nutrition (641)
- Oncology (2282)
- Ophthalmology (648)
- Orthopedics (258)
- Otolaryngology (326)
- Pain Medicine (279)
- Palliative Medicine (83)
- Pathology (502)
- Pediatrics (1199)
- Primary Care Research (499)
- Public and Global Health (6969)
- Radiology and Imaging (1537)
- Respiratory Medicine (917)
- Rheumatology (442)
- Sports Medicine (385)
- Surgery (491)
- Toxicology (60)
- Transplantation (212)
- Urology (182)